SACITUZUMAB GOVITECAN-HZIY Home | Cancer | Solid Tumors | SACITUZUMAB GOVITECAN-HZIY
SACITUZUMAB GOVITECAN-HZIY Injection Description Composition Dosage Indications TRODELVY (sacituzumab govitecan-hziy) is a Trop-2 directed antibody and topoisomerase inhibitor conjugate, composed of the following three components: • the humanized monoclonal antibody, hRS7 IgG1κ (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2); • the drug SN-38, a topoisomerase inhibitor; • a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN38.... * TRODELVY (sacituzumab govitecan-hziy) for injection is a sterile, preservative-free, off-white to yellowish lyophilized powder for intravenous use in a 50 mL clear glass singledose vial, with a rubber stopper and crimp-sealed with an aluminum flip-off cap. nWhere n~7.6 SN-38/Mab *Each single-dose vial of TRODELVY delivers 180 mg sacituzumab govitecan-hziy, 77.3 mg 2-(N-morpholino) ethane sulfonic acid (MES), 1.8 mg polysorbate 80 and 154 mg trehalose dihydrate. Reconstitution with 20 mL of 0.9% Sodium Chloride Injection, USP, results in a concentration of 10 mg/mL.
Copyright © 2024 ImpoMed
Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API
Printed with Pdfcrowd.com